Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Q A Mekki"'
Autor:
L J Mengle-Gaw, W Wisememandle, F X Burch, Daniel E. Furst, B D Schwartz, David E. Yocum, William G. Bensen, M A Borton, Q A Mekki
Publikováno v:
Rheumatology. 43:992-999
To evaluate the long-term safety of tacrolimus 3 mg/day in patients with rheumatoid arthritis (RA).Patients with active RA who had discontinued all DMARDs for at least 2 weeks and had at least five tender/painful joints and three swollen joints, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7df281daff5450586a03f5cd6ee858a3
https://doi.org/10.1093/rheumatology/keh155
https://doi.org/10.1093/rheumatology/keh155
Autor:
D. E. Furst, W. G. Bensen, F. X. Burch, M. A. Borton, L. J. Mengle-Gaw, B. D. Schwartz, W. Wisememandle, Q. A. Mekki
Publikováno v:
Rheumatology; Aug2004, Vol. 43 Issue 8, p992-999, 8p
Publikováno v:
British Journal of Ophthalmology. 72:598-600
We have shown that metoclopramide, a dopamine-2 antagonist, failed to antagonise the ocular hypotensive action of timolol. The practical implication of combining dopamine agonists with beta-adrenoceptor antagonists in the treatment of glaucoma is dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd734f12398b9fa424a28f3676e1456
https://doi.org/10.1136/bjo.72.8.598
https://doi.org/10.1136/bjo.72.8.598
Autor:
Q A Mekki, Paul Turner
Publikováno v:
British journal of clinical pharmacology. 26(1)
Two oral doses of cicloprolol (50 mg and 100 mg), a beta 1-adrenoceptor partial agonist, were administered to nine healthy volunteers in a double-blind placebo-controlled study. Intraocular pressure (IOP) and exercise heart rate were reduced while th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69784d94325e4b54721c024296d7101c
https://pubmed.ncbi.nlm.nih.gov/2904826
https://pubmed.ncbi.nlm.nih.gov/2904826
Publikováno v:
Prostaglandins. 29(1)
Following an open pilot study, the effects of repeated oral doses of BW245C, a hydantoin prostaglandin analogue, were studied in man. Six healthy volunteers received 150 micrograms BW245C or placebo 6-hourly for 5 days according to a double blind ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f403a2df36fc920c9afe7af3e38effd0
https://pubmed.ncbi.nlm.nih.gov/3975430
https://pubmed.ncbi.nlm.nih.gov/3975430
Autor:
S. Hassan, A. Hedges, BJ Whittle, Q. A. Mekki, J O'Grady, L. A.-H. Al-Sinawi, MJ Moti, S. G. Moody, C Burke
The effects of 9 beta-methyl carbacyclin, a chemically stable analogue of epoprostenol (prostacyclin, PGI2) were studied, in comparison with epoprostenol, both in vitro and in vivo in man. In vitro 9 beta-methyl carbacyclin and epoprostenol inhibited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d743bad95a917e02d95a4030219bd68
https://europepmc.org/articles/PMC1463693/
https://europepmc.org/articles/PMC1463693/
Publikováno v:
European journal of clinical pharmacology. 28(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5460a7a40720b59ef0a88c24d7c1afac
https://pubmed.ncbi.nlm.nih.gov/4029254
https://pubmed.ncbi.nlm.nih.gov/4029254
Local (reduction of intraocular pressure) and systemic (inhibition of exercise-induced tachycardia) effects of 1% and 0.25% pindolol eye drops have been studied in a balanced cross-over double-blind trial in 12 healthy volunteers. Both concentrations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e15afee1387380cb23c54ad114eef97
https://europepmc.org/articles/PMC1427832/
https://europepmc.org/articles/PMC1427832/
Publikováno v:
British Journal of Ophthalmology. 69:909-910
The interaction between bromocriptine and metoclopramide on intraocular pressure (IOP), pupil diameter, and other parameters were studied in healthy volunteers. Pupil diameter was not affected by both treatments and only bromocriptine lowered IOP. Pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e110e4742a113ff8cc98bf7c425a2e8
https://doi.org/10.1136/bjo.69.12.909
https://doi.org/10.1136/bjo.69.12.909